Table 3.
Diverse neutralizing epitopes and putative N-glycosylation sties on GP5 of Korean field PRRSVs isolated in 2003–2016 and commercial vaccine strains
| Type | Vaccine strain/Isolated year | Subgroup /Lineage | AA sequence of neutralizing epitopes | AA position for putative N-glycosylation sites |
|---|---|---|---|---|
| 1 | DV | subgroup C | WSFADGN | 37-46-53 |
| VP-046 | subgroup A | WSFVDGN | 35-46-53 | |
| 2005-2009 | subgroup A | WSFADGN(71)a, WSFVDGN(1), WSFADGS(3), WSFASGN(1), WSFADCN(1) | 37-46-53(75), 37-53(2) | |
| subgroup B | WSFADGN(2), WSFANGN(1), WSFVDGS(1) | 37-46-53(3), 37-53(1) | ||
| 2013-2016 | subgroup A | WSFADGN(214), WSFAYGN(1), WSFVDGN(5), WSFADGT(7), WSFADGS(11), WSSADGR(1), WSFADGK(2), WSFANGN(1), WSFADGD(2), WSSADGS(3), WPFADGN(4), WSSADGN(5), CSFAAGS(4), WSSADGE(1), WSFADGA(1), WSFADAN(1), WPFAAGS(3), WSFAGGN(2), WSFAEGN(1), WSSANGS(1), LSFVDCN(1), WPFAEGN(1), YSSANGN(1), LSYADGS(1) | 37-46-53 (252), 37-53 (12), 35-46-53 (2), 33-37-46-53 (1), 37-46-53-61(2), 37-38-46-53(2), 46-53(1), 36-46-53(1), 46 (1) | |
| subgroup B | WSFANGN(1) | 37-46-53(1) | ||
| subgroup C | WSFADGN(15), WSFVDGN(1), WSFVDGS(2), WSFADGS(1), WSFANGN(1) | 37-46-53(14), 35-46-53(4), 37-53(2) | ||
| 2 | IngelvacPRRS MLV | lineage 5 | SHLQLIYNL | 30-33-44-51 |
| P129 | lineage 8 | SHFQLIYNL | 32-44-51 | |
| 2003-2010 | lineage 4 | SHLQLIYNL | 30-33-44-51 | |
| lineage 5 | SHLQLIYNL(43), SNLQLIYNL(11), SKFQLIYNL(1), XNLQLIYNL(1), SNLQSIYNL(1) | 30-33-44-51(17), 34-44-51(17), 32-33-44-51(7), 33-34-44-51(3), 32-44-51(2), 30-35-44-51(1), 30-33-43-50(1), 30-33-34-44-51(4), 30-34-44-51(3), 30-34-35-44-51(1), 33-44-51(1) | ||
| lineage kor A | SHFQLIYNL(9), SHLQLIYNL(1), SKFQLIYNL(1), SKIQLIYNL(2), SHIQLIYNL(1), SKLQSIYKL(1), SNLQLIYNL(2), SNFQLIYNL(4), SKLQLIYNL(3) | 32-44-51(5), 33-44-51(5), 33-51(1), 32-33-44-51(3), 32-43-50(1), 35-43-50(1), 33-43-50(3), 30-33-44-51(1), 34-44-51(2), 33-34-44-51(1), 30-35-44-51(1) | ||
| lineage kor C | SHLQLIYNL(24), SHLQSIYNL(8) | 30-34-44-51(13), 34-44-51(3), 30-44-51(1), 30-33-44-51(2), 33-34-44-51(5), 30-33-34-44-51(4), 30-35-44-51(2), 33-44-51(2) | ||
| 2013-2016 | lineage 1 | SHLQLIYNL(9) | 30-33-34-44-51(4), 30-34-44-51(1), 34-44-51-59(2), 33-34-44-51(1), 30-33-44-51(1) | |
| lineage 5 | SHLQLIYNL(77), SKFQLIYNL(2), SNLQLIYNL(3), SRLQSIYNL(1) | 30-33-44-51(48), 32-35-44-51(1), 33-34-44-51(4), 30-33-34-44-51(10), 34-44-51(7), 30-33-43-50(2), 30-44-51(2), 30-35-44-51(4), 32-33-44-51(3), 33-44-51(2) | ||
| lineage kor A | SHFQLIYNL(14), SHLQLIYNL(2), SKFQLIYNL(2), SNLQLIYNL(1), SYSQLIYNL(4), SYSQSIYDL(1), SYSQSIYNL(1), SKLQLIYNL(4), SKLQLIYNM(1), SNFQLIYNL(2), SHIQLIYNL(1) | 34-44-51(17), 33-44-51(3), 32-33-44-51(6), 32-44-51(3), 32-35-44-51(2), 33-34-44-51(1), 32-51 (1) | ||
| lineage kor B | SNLQLIYNL(47), SHLQLIYNL(2), STLQLIYNL(12), STSQLIYNL(1), SKLQLIYNL(7), SNPQLIYNL(1), SKLQLIYDL(1),SHLQSIYNL(1) | 34-44-51(39), 34-43-50(2), 34-35-44-51(6), 33-44-51(4), 34-51(1), 33-44-51(1), 32-44-51(8), 33-43-50(1), 33-34-44-51(9), 32-33-44-51(1) | ||
| lineage kor C | SHLQLIYNL(38), SHLQLIYKM(1), SHLQSIYNL(4), SHSQLIYNL(1), SHFQSIYNL(1), SHLQLIYDL(1), SQLQLIYNL(3), SHLQLIYKL(1) | 30-33-44-51(8), 30-35-44-51(6), 34-44-51(5), 30-34-44-51 (4), 32-35-44-51(1), 32-33-44-51(2), 33-51(1), 30-34-35-44-51 (4), 33-34-44-51(2), 35-51(1), 34-35-44-51(3), 33-44-51 (6), 30-33-51(1), 30-33-34-44-51(5), 35-44-51(1) |
aMain neutralizing epitope and pattern of N-glycosylation site at each subgroup or lineage were underlined